PD-1/PD-L1 pathway in breast cancer

• Verfasst von: Schütz, Florian [VerfasserIn]
• Verfasst von: Stefanovic, Stefan [VerfasserIn]
• Verfasst von: Mayer, Luisa [VerfasserIn]
• Verfasst von: Au, Alexandra von [VerfasserIn]
• Verfasst von: Domschke, Christoph [VerfasserIn]
• Verfasst von: Sohn, Christof [VerfasserIn]
• Titel: PD-1/PD-L1 pathway in breast cancer
• Verf.angabe: Florian Schütz, Stefan Stefanovic, Luisa Mayer, Alexandra von Au, Christoph Domschke, Christof Sohn
• E-Jahr: 2017
• Jahr: March 27, 2017
• Umfang: 4 S.
• Fussnoten: Gesehen am 20.04.2018
• Titel Quelle: Enthalten in: Oncology research and treatment
• Ort Quelle: Basel : Karger, 2014
• Jahr Quelle: 2017
• Band/Heft Quelle: 40(2017), 5, Seite 294-297
• ISSN Quelle: 2296-5262
• DOI: doi:10.1159/000464353
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1572223235

Abstract

The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and regulating inflammation. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers.